Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026)
Soleno Therapeutics (SLNO) reported EBITDA Margin of 30.79% for Q1 2026, down 34.95% quarter-over-quarter from 47.33% in Q4 2025.
Soleno Therapeutics (SLNO) EBITDA Margin (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 5 years of EBITDA Margin data on file, last reported at 30.79% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 30.79%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 32.97% (changed N/A YoY), and the FY2025 annual result was 11.0%, changed N/A from the prior year.
- EBITDA Margin eased to 30.79% in Q1 2026 per SLNO's latest filing, from 47.33% in the prior quarter.
- Over five years, EBITDA Margin peaked at 47.33% in Q4 2025 and troughed at 14.85% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 30.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.79% |
| Dec 31, 2025 | 47.33% |
| Sep 30, 2025 | 39.82% |
| Jun 30, 2025 | -14.85% |
| Jun 30, 2017 | -296,800.00% |
| Mar 31, 2017 | -518.11% |
| Dec 31, 2016 | -126.35% |
| Sep 30, 2016 | -598.18% |
| Jun 30, 2016 | -114,750.00% |
| Mar 31, 2016 | -953.69% |
| Dec 31, 2015 | -4,744.17% |
| Sep 30, 2015 | -11,788.89% |
| Jun 30, 2015 | -3,138.14% |
| Mar 31, 2015 | -11,027.27% |